Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where COEP declined for three days, in of 208 cases, the price declined further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for COEP moved out of overbought territory on April 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where COEP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on April 30, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on COEP as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for COEP turned negative on April 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at .
COEP moved below its 50-day moving average on April 25, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COEP crossed bearishly below the 50-day moving average on May 02, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
COEP broke above its upper Bollinger Band on April 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where COEP advanced for three days, in of 186 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 152 cases where COEP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. COEP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.804) is normal, around the industry mean (14.243). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (253.449).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COEP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Industry Biotechnology
A.I.dvisor indicates that over the last year, COEP has been loosely correlated with SNPX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if COEP jumps, then SNPX could also see price increases.
Ticker / NAME | Correlation To COEP | 1D Price Change % | ||
---|---|---|---|---|
COEP | 100% | +5.93% | ||
SNPX - COEP | 37% Loosely correlated | +1.67% | ||
TVRD - COEP | 37% Loosely correlated | +0.19% | ||
LOGC - COEP | 35% Loosely correlated | +2.50% | ||
SCNI - COEP | 31% Poorly correlated | N/A | ||
TIL - COEP | 31% Poorly correlated | +5.42% | ||
More |